5AM Venture Management LLC Has $14.53 Million Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

5AM Venture Management LLC lessened its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 14.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 580,945 shares of the company’s stock after selling 100,000 shares during the period. Centessa Pharmaceuticals makes up about 4.6% of 5AM Venture Management LLC’s investment portfolio, making the stock its 9th biggest holding. 5AM Venture Management LLC’s holdings in Centessa Pharmaceuticals were worth $14,529,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Foresite Capital Management VI LLC increased its stake in Centessa Pharmaceuticals by 4.8% in the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after purchasing an additional 60,640 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $2,500,000. SG Americas Securities LLC raised its holdings in shares of Centessa Pharmaceuticals by 1,017.7% during the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after acquiring an additional 240,039 shares during the period. Royce & Associates LP bought a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $5,999,000. Finally, Cinctive Capital Management LP acquired a new position in Centessa Pharmaceuticals in the 3rd quarter worth $2,246,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CNTA shares. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Monday, April 13th. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Finally, Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $39.87 on Thursday. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $12.30 and a 12 month high of $40.26. The firm has a fifty day simple moving average of $39.65 and a 200 day simple moving average of $31.11. The stock has a market capitalization of $6.17 billion, a price-to-earnings ratio of -22.27 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.